HRP20100042T1 - ANTAGONIST CaSR - Google Patents
ANTAGONIST CaSR Download PDFInfo
- Publication number
- HRP20100042T1 HRP20100042T1 HR20100042T HRP20100042T HRP20100042T1 HR P20100042 T1 HRP20100042 T1 HR P20100042T1 HR 20100042 T HR20100042 T HR 20100042T HR P20100042 T HRP20100042 T HR P20100042T HR P20100042 T1 HRP20100042 T1 HR P20100042T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- methylpropan
- ethyl
- carboxylic acid
- hydroxypropoxy
- Prior art date
Links
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 title 1
- 101710159793 Extracellular calcium-sensing receptor Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 31
- 150000001875 compounds Chemical class 0.000 claims abstract 22
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 9
- 229910052736 halogen Inorganic materials 0.000 claims abstract 9
- 125000005843 halogen group Chemical group 0.000 claims abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims abstract 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000004442 acylamino group Chemical group 0.000 claims abstract 2
- 125000003277 amino group Chemical group 0.000 claims abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 229940126585 therapeutic drug Drugs 0.000 claims 5
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- QWDVXOKNZUMCHX-MQNHUJCZSA-N 4-[2-[1-[(2r)-3-[[1-(3-chloro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C)C(C(O)=O)=CC=1)NC(C)(C)CC1=CC=C(C)C(Cl)=C1 QWDVXOKNZUMCHX-MQNHUJCZSA-N 0.000 claims 3
- XUZPXYZNDHHEST-MQNHUJCZSA-N 4-[2-[1-[(2r)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C)C(C(O)=O)=CC=1)NC(C)(C)CC1=CC=C(C)C(F)=C1 XUZPXYZNDHHEST-MQNHUJCZSA-N 0.000 claims 3
- AQPYANXMGDKLLM-LEQGEALCSA-N 4-[2-[1-[(2r)-3-[[1-(4-chloro-2-fluorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C)C(C(O)=O)=CC=1)NC(C)(C)CC1=CC=C(Cl)C=C1F AQPYANXMGDKLLM-LEQGEALCSA-N 0.000 claims 3
- 108090000445 Parathyroid hormone Proteins 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- UNFHDRVFEQPUEL-AVKWCDSFSA-N 4-[2-[1-[(2r)-3-[[1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C)C(C(O)=O)=CC=1)NC(C)(C)CC1=CC=C(Cl)C(F)=C1 UNFHDRVFEQPUEL-AVKWCDSFSA-N 0.000 claims 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims 2
- 239000000199 parathyroid hormone Substances 0.000 claims 2
- 229960001319 parathyroid hormone Drugs 0.000 claims 2
- BVSXVRSNMHHYJM-GMLYINLCSA-N 2-butan-2-yl-4-[2-[1-[(2r)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]benzoic acid Chemical compound C1=C(C(O)=O)C(C(C)CC)=CC(C=2C(=CC=CC=2)C(C)OC[C@H](O)CNC(C)(C)CC=2C=C(F)C(C)=CC=2)=C1 BVSXVRSNMHHYJM-GMLYINLCSA-N 0.000 claims 1
- KMLSIUHKVREJTG-UIDYPRJRSA-N 2-ethyl-4-[2-[1-[(2r)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]benzoic acid Chemical compound C1=C(C(O)=O)C(CC)=CC(C=2C(=CC=CC=2)C(C)OC[C@H](O)CNC(C)(C)CC=2C=C(F)C(C)=CC=2)=C1 KMLSIUHKVREJTG-UIDYPRJRSA-N 0.000 claims 1
- UCZFIUQTYKVEIZ-NRWPOFLRSA-N 2-tert-butyl-4-[2-[1-[(2r)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]benzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C(C(O)=O)=CC=1)C(C)(C)C)NC(C)(C)CC1=CC=C(C)C(F)=C1 UCZFIUQTYKVEIZ-NRWPOFLRSA-N 0.000 claims 1
- YOHPPVDKKZZAMD-PIFIWZBESA-N 2-tert-butyl-4-[2-[1-[(2r)-3-[[1-(4-chloro-2-fluorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]benzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C(C(O)=O)=CC=1)C(C)(C)C)NC(C)(C)CC1=CC=C(Cl)C=C1F YOHPPVDKKZZAMD-PIFIWZBESA-N 0.000 claims 1
- MMCQSLBONUTOPC-GWQXNCQPSA-N 2-tert-butyl-4-[2-[1-[(2r)-3-[[1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]benzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C(C(O)=O)=CC=1)C(C)(C)C)NC(C)(C)CC1=CC=C(Cl)C(F)=C1 MMCQSLBONUTOPC-GWQXNCQPSA-N 0.000 claims 1
- FWRORUOBZZYGEM-NRWPOFLRSA-N 3-[1-[(2r)-2-hydroxy-3-[[1-(3-methoxy-4-methylphenyl)-2-methylpropan-2-yl]amino]propoxy]ethyl]-2-methyl-4-phenylbenzoic acid Chemical compound C1=C(C)C(OC)=CC(CC(C)(C)NC[C@@H](O)COC(C)C=2C(=CC=C(C=2C)C(O)=O)C=2C=CC=CC=2)=C1 FWRORUOBZZYGEM-NRWPOFLRSA-N 0.000 claims 1
- ZCVHRWIVWANFEO-AVKWCDSFSA-N 3-[1-[(2r)-3-[[1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-2-methyl-4-phenylbenzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=C(C=1C)C(O)=O)C=1C=CC=CC=1)NC(C)(C)CC1=CC=C(Cl)C(F)=C1 ZCVHRWIVWANFEO-AVKWCDSFSA-N 0.000 claims 1
- KMCHMNAFFOITSJ-NRWPOFLRSA-N 4-[2-[1-[(2r)-2-hydroxy-3-[[2-methyl-1-(4-methylphenyl)propan-2-yl]amino]propoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C)C(C(O)=O)=CC=1)NC(C)(C)CC1=CC=C(C)C=C1 KMCHMNAFFOITSJ-NRWPOFLRSA-N 0.000 claims 1
- AYQOHBNPZWTGAI-MQNHUJCZSA-N 4-[2-[1-[(2r)-2-hydroxy-3-[[2-methyl-1-[4-methyl-3-(trifluoromethyl)phenyl]propan-2-yl]amino]propoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C)C(C(O)=O)=CC=1)NC(C)(C)CC1=CC=C(C)C(C(F)(F)F)=C1 AYQOHBNPZWTGAI-MQNHUJCZSA-N 0.000 claims 1
- LOQSCOCDKVOMRW-MQNHUJCZSA-N 4-[2-[1-[(2r)-3-[[1-(2-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C)C(C(O)=O)=CC=1)NC(C)(C)CC1=CC=C(C)C=C1F LOQSCOCDKVOMRW-MQNHUJCZSA-N 0.000 claims 1
- UEPUDNFKFGPBLV-AVKWCDSFSA-N 4-[2-[1-[(2r)-3-[[1-(3,4-dichlorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C)C(C(O)=O)=CC=1)NC(C)(C)CC1=CC=C(Cl)C(Cl)=C1 UEPUDNFKFGPBLV-AVKWCDSFSA-N 0.000 claims 1
- UEIYKAQGJKLYCY-ANWICMFUSA-N 4-[2-[1-[(2r)-3-[[1-(3,4-dimethylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C)C(C(O)=O)=CC=1)NC(C)(C)CC1=CC=C(C)C(C)=C1 UEIYKAQGJKLYCY-ANWICMFUSA-N 0.000 claims 1
- LVXDYQNXYOUDIO-JKSFWZLDSA-N 4-[2-[1-[(2r)-3-[[1-(3,5-dichlorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C)C(C(O)=O)=CC=1)NC(C)(C)CC1=CC(Cl)=CC(Cl)=C1 LVXDYQNXYOUDIO-JKSFWZLDSA-N 0.000 claims 1
- VVSQPNBBZONYQI-PIFIWZBESA-N 4-[2-[1-[(2r)-3-[[1-(3-chlorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C)C(C(O)=O)=CC=1)NC(C)(C)CC1=CC=CC(Cl)=C1 VVSQPNBBZONYQI-PIFIWZBESA-N 0.000 claims 1
- NTVGSOANQXUMDG-IQHZPMLTSA-N 4-[2-[1-[(2r)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-(2-methylpropyl)benzoic acid Chemical compound C1=C(C(O)=O)C(CC(C)C)=CC(C=2C(=CC=CC=2)C(C)OC[C@H](O)CNC(C)(C)CC=2C=C(F)C(C)=CC=2)=C1 NTVGSOANQXUMDG-IQHZPMLTSA-N 0.000 claims 1
- MLPLNOFBZGWUMY-ZWAGFTRDSA-N 4-[2-[1-[(2r)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-propylbenzoic acid Chemical compound C1=C(C(O)=O)C(CCC)=CC(C=2C(=CC=CC=2)C(C)OC[C@H](O)CNC(C)(C)CC=2C=C(F)C(C)=CC=2)=C1 MLPLNOFBZGWUMY-ZWAGFTRDSA-N 0.000 claims 1
- DESSTMCVVPPDLN-GWQXNCQPSA-N 4-[2-[1-[(2r)-3-[[1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-propan-2-ylbenzoic acid Chemical compound C1=C(C(O)=O)C(C(C)C)=CC(C=2C(=CC=CC=2)C(C)OC[C@H](O)CNC(C)(C)CC=2C=C(F)C(Cl)=CC=2)=C1 DESSTMCVVPPDLN-GWQXNCQPSA-N 0.000 claims 1
- MMIBOSUVABWADQ-MQNHUJCZSA-N 4-[2-[1-[(2r)-3-[[1-(4-chloro-3-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C([C@@H](O)COC(C)C=1C(=CC=CC=1)C=1C=C(C)C(C(O)=O)=CC=1)NC(C)(C)CC1=CC=C(Cl)C(C)=C1 MMIBOSUVABWADQ-MQNHUJCZSA-N 0.000 claims 1
- SPDZMDPQBQFFLC-UIDYPRJRSA-N 4-[2-[1-[(2r)-3-[[1-(4-ethyl-3-fluorophenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C1=C(F)C(CC)=CC=C1CC(C)(C)NC[C@@H](O)COC(C)C1=CC=CC=C1C1=CC=C(C(O)=O)C(C)=C1 SPDZMDPQBQFFLC-UIDYPRJRSA-N 0.000 claims 1
- MYAHGDDNTAEJIN-ZWAGFTRDSA-N 4-[2-[1-[(2r)-3-[[1-(4-ethylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]phenyl]-2-methylbenzoic acid Chemical compound C1=CC(CC)=CC=C1CC(C)(C)NC[C@@H](O)COC(C)C1=CC=CC=C1C1=CC=C(C(O)=O)C(C)=C1 MYAHGDDNTAEJIN-ZWAGFTRDSA-N 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229940123613 Calcium receptor antagonist Drugs 0.000 claims 1
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 claims 1
- 102100036893 Parathyroid hormone Human genes 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229930003448 Vitamin K Natural products 0.000 claims 1
- 239000003263 anabolic agent Substances 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229960005431 ipriflavone Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 1
- 230000000580 secretagogue effect Effects 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 235000019168 vitamin K Nutrition 0.000 claims 1
- 239000011712 vitamin K Substances 0.000 claims 1
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 229940046010 vitamin k Drugs 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003119131 | 2003-04-23 | ||
| PCT/JP2004/005886 WO2004094362A1 (ja) | 2003-04-23 | 2004-04-23 | CaSRアンタゴニスト |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100042T1 true HRP20100042T1 (hr) | 2010-02-28 |
Family
ID=33308093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100042T HRP20100042T1 (hr) | 2003-04-23 | 2010-01-22 | ANTAGONIST CaSR |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US7304174B2 (es) |
| EP (3) | EP2189439A3 (es) |
| JP (1) | JP3751312B2 (es) |
| KR (1) | KR100696927B1 (es) |
| CN (2) | CN101723921A (es) |
| AR (1) | AR044075A1 (es) |
| AT (1) | ATE452121T1 (es) |
| AU (1) | AU2004232604C1 (es) |
| BR (1) | BRPI0407097A (es) |
| CA (1) | CA2513738C (es) |
| CL (1) | CL2004000868A1 (es) |
| CO (1) | CO5640091A2 (es) |
| CY (1) | CY1109880T1 (es) |
| DE (1) | DE602004024668D1 (es) |
| DK (1) | DK1619180T3 (es) |
| ES (1) | ES2337576T3 (es) |
| HK (1) | HK1083096A1 (es) |
| HR (1) | HRP20100042T1 (es) |
| IL (1) | IL169575A (es) |
| MX (1) | MXPA05007609A (es) |
| MY (1) | MY138734A (es) |
| NO (1) | NO20054868L (es) |
| NZ (1) | NZ541188A (es) |
| PE (1) | PE20050460A1 (es) |
| PL (1) | PL1619180T3 (es) |
| PT (1) | PT1619180E (es) |
| RU (1) | RU2315036C2 (es) |
| SI (1) | SI1619180T1 (es) |
| TW (1) | TWI329628B (es) |
| WO (1) | WO2004094362A1 (es) |
| ZA (1) | ZA200505587B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| WO2004106280A1 (ja) * | 2003-05-28 | 2004-12-09 | Japan Tobacco Inc. | ＣａＳＲアンタゴニスト |
| US20070155819A1 (en) * | 2004-02-06 | 2007-07-05 | Marquis Robert W Jr | Calcilytic compounds |
| WO2007124465A2 (en) * | 2006-04-20 | 2007-11-01 | Amgen Inc. | Stable emulsion formulations |
| WO2008121386A2 (en) | 2007-03-30 | 2008-10-09 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
| EP2292592B1 (en) * | 2008-06-05 | 2012-09-05 | Asahi Kasei Pharma Corporation | Sulfonamide compound and application thereof |
| CN102307847A (zh) | 2008-12-24 | 2012-01-04 | 第一三共株式会社 | 茚满基化合物 |
| RU2478616C2 (ru) * | 2008-12-24 | 2013-04-10 | Дайити Санкио Компани, Лимитед | Циклические аминосоединения |
| WO2010104882A1 (en) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Methods of modulating sperm motility |
| WO2010103429A1 (en) * | 2009-03-10 | 2010-09-16 | Pfizer Inc. | 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists |
| CN102365261A (zh) * | 2009-03-26 | 2012-02-29 | 日本烟草产业株式会社 | 制备羧酸化合物的方法 |
| WO2010113860A1 (ja) * | 2009-03-31 | 2010-10-07 | 第一三共株式会社 | ビフェニル－環状アミン化合物 |
| CA2762137A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| US8785494B2 (en) | 2009-05-27 | 2014-07-22 | Leo-Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| US20130267516A1 (en) * | 2010-11-26 | 2013-10-10 | Leo Pharma A/S | Substituted cyclopentyl-azines as casr-active compounds |
| RU2013128973A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Соединения, активные в отношении кальций-чувствительных рецепторов |
| US20130261132A1 (en) | 2010-11-26 | 2013-10-03 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| US20130244995A1 (en) | 2010-11-26 | 2013-09-19 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| GB201113538D0 (en) * | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| US9227919B2 (en) * | 2012-08-27 | 2016-01-05 | Lupin Limited | Arylalkylamine compounds as calcium sensing receptor modulators |
| WO2017215591A1 (en) | 2016-06-13 | 2017-12-21 | Syneurx International (Taiwan) Corp. | Use of lithium benzoate for treating central nervous system disorders |
| BR112022011127A2 (pt) * | 2019-12-09 | 2022-08-23 | Beijing Tuo Jie Biopharmaceutical Co Ltd | Composto agonista do receptor de detecção de cálcio e aplicação do mesmo |
| CN116648243A (zh) | 2020-08-04 | 2023-08-25 | 柯西立提克斯疗法有限公司 | 三苯基钙敏感化合物的制剂 |
| EP4213829A1 (en) | 2020-09-18 | 2023-07-26 | Calcilytix Therapeutics, Inc. | Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE633760A (es) * | 1963-06-18 | |||
| DD207203A1 (de) * | 1982-06-21 | 1984-02-22 | Peter Meisel | Verfahren zur herstellung von epoxypropylethern |
| DE3743265A1 (de) * | 1987-12-19 | 1989-06-29 | Boehringer Ingelheim Kg | Neue ammoniumverbindungen, ihre herstellung und verwendung |
| US5276008A (en) * | 1990-08-09 | 1994-01-04 | Bayer Aktiengesellschaft | Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones |
| US6818660B2 (en) | 1996-04-09 | 2004-11-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
| US6022894A (en) | 1996-04-09 | 2000-02-08 | Nps Pharmaceuticals, Inc. | Method of using calcilytic compounds |
| ATE215369T1 (de) * | 1996-09-05 | 2002-04-15 | Lilly Co Eli | Carbazolanaloge als selektive beta3-adrenergische agonisten |
| UY24949A1 (es) | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
| AR014975A1 (es) | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
| US20020052509A1 (en) | 1998-04-08 | 2002-05-02 | Smithkline Beecham Corporation | Calcilytic compounds and method of use |
| PE20000415A1 (es) | 1998-04-08 | 2000-05-21 | Smithkline Beecham Corp | Compuestos calciliticos |
| US6334338B1 (en) | 1998-07-02 | 2002-01-01 | Lucent Technologies Inc. | Sol gel process of making a fiber preform with removal of oxide particles |
| WO2000009132A1 (en) | 1998-08-12 | 2000-02-24 | Smithkline Beecham Corporation | Calcilytic compounds |
| EP1104411A4 (en) | 1998-08-12 | 2002-10-24 | Smithkline Beecham Corp | CALCILYTIC COMPOUNDS |
| HUP0104199A3 (en) * | 1998-10-23 | 2002-12-28 | Hoffmann La Roche | Substituted pyrimido pyrimidinone derivatives, pharmaceutical compositions containing the same, process for the preparation thereof and intermediates |
| PE20001456A1 (es) | 1999-02-02 | 2001-01-28 | Smithkline Beecham Corp | Compuestos calcioliticos |
| BR0013610A (pt) * | 1999-08-27 | 2002-07-16 | Procter & Gamble | Componentes de formulções de ação rápida,composições e métodos para lavar roupa empregando os mesmos |
| IL139073A0 (en) | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
| AR030684A1 (es) | 2000-01-24 | 2003-09-03 | Smithkline Beecham Corp | Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos |
| US20030018203A1 (en) | 2002-07-17 | 2003-01-23 | Largo Maria Amparo | Calcilytic compounds |
| US6867299B2 (en) * | 2000-02-24 | 2005-03-15 | Hoffmann-La Roche Inc. | Oxamide IMPDH inhibitors |
| AU2001276923B2 (en) | 2000-07-21 | 2005-02-03 | Smithkline Beecham Corporation | Calcilytic compounds |
| ATE411275T1 (de) | 2000-08-11 | 2008-10-15 | Japan Tobacco Inc | Calciumrezeptor-antagonisten |
| AU2002230579A1 (en) | 2000-10-25 | 2002-05-06 | Smithkline Beecham Corp | Calcilytic compounds |
| JP2004519428A (ja) | 2000-10-25 | 2004-07-02 | スミスクライン・ビーチャム・コーポレイション | カルシライティック化合物 |
| AR038658A1 (es) | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
| US6864267B2 (en) | 2001-07-16 | 2005-03-08 | Smithkline Beecham Corporation | Calcilytic compounds |
| WO2004106280A1 (ja) * | 2003-05-28 | 2004-12-09 | Japan Tobacco Inc. | ＣａＳＲアンタゴニスト |
-
2004
- 2004-04-23 CL CL200400868A patent/CL2004000868A1/es unknown
- 2004-04-23 ZA ZA200505587A patent/ZA200505587B/en unknown
- 2004-04-23 EP EP09177717A patent/EP2189439A3/en not_active Withdrawn
- 2004-04-23 NZ NZ541188A patent/NZ541188A/en not_active IP Right Cessation
- 2004-04-23 ES ES04729243T patent/ES2337576T3/es not_active Expired - Lifetime
- 2004-04-23 AT AT04729243T patent/ATE452121T1/de active
- 2004-04-23 BR BR0407097-6A patent/BRPI0407097A/pt not_active IP Right Cessation
- 2004-04-23 DK DK04729243.8T patent/DK1619180T3/da active
- 2004-04-23 TW TW093111360A patent/TWI329628B/zh not_active IP Right Cessation
- 2004-04-23 CN CN200910253477A patent/CN101723921A/zh active Pending
- 2004-04-23 KR KR1020057013977A patent/KR100696927B1/ko not_active IP Right Cessation
- 2004-04-23 MY MYPI20041512A patent/MY138734A/en unknown
- 2004-04-23 AU AU2004232604A patent/AU2004232604C1/en not_active Ceased
- 2004-04-23 US US10/830,480 patent/US7304174B2/en active Active
- 2004-04-23 WO PCT/JP2004/005886 patent/WO2004094362A1/ja active Application Filing
- 2004-04-23 CN CN200480002843A patent/CN100577633C/zh not_active Expired - Fee Related
- 2004-04-23 PT PT04729243T patent/PT1619180E/pt unknown
- 2004-04-23 DE DE602004024668T patent/DE602004024668D1/de not_active Expired - Lifetime
- 2004-04-23 RU RU2005123985/04A patent/RU2315036C2/ru not_active IP Right Cessation
- 2004-04-23 AR ARP040101388A patent/AR044075A1/es unknown
- 2004-04-23 JP JP2005505801A patent/JP3751312B2/ja not_active Expired - Lifetime
- 2004-04-23 EP EP10179435.2A patent/EP2308828A3/en not_active Withdrawn
- 2004-04-23 PL PL04729243T patent/PL1619180T3/pl unknown
- 2004-04-23 CA CA2513738A patent/CA2513738C/en not_active Expired - Fee Related
- 2004-04-23 MX MXPA05007609A patent/MXPA05007609A/es active IP Right Grant
- 2004-04-23 PE PE2004000403A patent/PE20050460A1/es not_active Application Discontinuation
- 2004-04-23 SI SI200431348T patent/SI1619180T1/sl unknown
- 2004-04-23 EP EP04729243A patent/EP1619180B1/en not_active Expired - Lifetime
-
2005
- 2005-07-07 IL IL169575A patent/IL169575A/en not_active IP Right Cessation
- 2005-10-19 CO CO05106148A patent/CO5640091A2/es active IP Right Grant
- 2005-10-21 NO NO20054868A patent/NO20054868L/no not_active Application Discontinuation
-
2006
- 2006-05-10 HK HK06105438.3A patent/HK1083096A1/xx not_active IP Right Cessation
-
2007
- 2007-08-17 US US11/840,739 patent/US20080255042A1/en not_active Abandoned
-
2009
- 2009-03-27 US US12/412,964 patent/US20090326058A1/en not_active Abandoned
-
2010
- 2010-01-22 HR HR20100042T patent/HRP20100042T1/hr unknown
- 2010-03-10 CY CY20101100234T patent/CY1109880T1/el unknown
-
2011
- 2011-12-23 US US13/336,205 patent/US20120301552A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100042T1 (hr) | ANTAGONIST CaSR | |
| EA200400154A1 (ru) | Новые лекарственные формы замещенного бензимидазола и способ их применения | |
| CN101516840B (zh) | 取代的n-酰基苯胺及其应用方法 | |
| ES2543007T3 (es) | Micropartículas que comprenden sales de dicetopiperazina para la administración de fármacos | |
| RU2409576C2 (ru) | Системы, содержащие имидазольное кольцо с заместителями, и способы их получения | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| RU2008130891A (ru) | Твердый препарат с контролируемым высвобождением | |
| ECSP055688A (es) | Nuevas formulaciones farmacéuticas sólidas que comprenden telmisartano y su preparación | |
| BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
| JP2007533686A (ja) | 性的障害ｉｉ治療用の新規医薬組成物 | |
| PT1419151E (pt) | Cristais que incluem um sal do ácido málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-di-hidro-2-oxo-3hindol- 3-ilideno)metil-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições | |
| PT1227806E (pt) | Formulacao farmaceutica contendo tolterodina e sua utilizacao | |
| JP2005536475A5 (es) | ||
| RU2010133524A (ru) | Борсодержащие малые молекулы | |
| RU2010139634A (ru) | Аналоги окситоцина | |
| PE20020531A1 (es) | Productos radiofarmaceuticos para el diagnostico de la enfermedad de alzheimer | |
| RU2011138962A (ru) | Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1 | |
| RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
| ATE344022T1 (de) | Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe | |
| BR0207872A (pt) | Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração | |
| RU2331635C2 (ru) | Производные гидрокси-тетрагидро-нафталенилмочевины | |
| CA2568445A1 (en) | Immediate release formulations of memantine oral dosage forms | |
| MEP10808A (en) | Solid drug for oral use | |
| EP1773740A4 (en) | COMPOUNDS WITH NEUROLOGICAL ACTIVITY | |
| TR200601092T1 (tr) | İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar. |